

XP-002171276

AN - 2001-294839 [31]

AP - JP19990237307 19990824

CPY - EGUC-I

- SCHN-N

- WATA-I

DC - B04 D16

FS - CPI

IC - A61K35/84 ; A61P3/06

MC - B04-A10A B04-F09 B14-F06 B14-S04 D05-A04C D05-H08

M1 - [01]

PA - (EGUC-I) EGUCHI F

- (SCHN-N) SCHNAPPS KK

- (WATA-I) WATANABE Y

PN - JP2001064194 A 20010313 DW200131 A61K35/84 005pp

PR - JP19990237307 19990824

XA - C2001-091109

XIC - A61K-035/84 ; A61P-003/06

AB - JP2001064194 NOVELTY - Anti-hyperlipemic comprising eryngii mushroom such as Pleurotus eryngii extract or dry powder, as active ingredient, is new.

- ACTIVITY - Anti-lipemic; Antidiabetic. 30 eight week old Wister male rat (body weight of 200g) was bred for 2 weeks with high fat diet containing 1 % cholesterol and 10 % lard. Blood was collected from ridges and blood cholesterol level was measured. The rats were divided into 6 groups of 5 each. Hot water extract of eryngii mushroom was administered to 3 groups at the rate of 600 ml/60 kg body weight. The other groups were used as the control. The rate of body weight gain of the control and test groups were measured and compared. The rate of body weight gain and abdominal fat content due to high fat diet was found to be unusually high in control whereas the animal administered with the extract were found to be free from undesirable body weight gain and fat content.

- MECHANISM OF ACTION - None given.

- USE - As anti-hyperlipemic for treating and preventing hyperlipidemia, as cholesterol reducing agent in treating hypercholesterolemia. As triglyceride reducing agent for treating hypertriglyceridemia.

- ADVANTAGE - The extract or powder does not produce any adverse effect, hence it is safe for use as antilipemic agent, for long-term, continuously.

- (Dwg.0/0)

IW - ANTI TREAT PREVENT COMPRISE MUSHROOM PLEUROTUS EXTRACT DRY POWDER ACTIVE INGREDIENT

IKW - ANTI TREAT PREVENT COMPRISE MUSHROOM PLEUROTUS EXTRACT DRY POWDER ACTIVE INGREDIENT

NC - 001

OPD - 1999-08-24

ORD - 2001-03-13

PAW - (EGUC-I) EGUCHI F

- (SCHN-N) SCHNAPPS KK

- (WATA-I) WATANABE Y

TI - Anti-hyperlipemic for treating and preventing hyperlipidemia,

THOMSON
DELPHION™

RESEARCH **PRODUCTS** **INSIDE DELPHION**

[Log Out](#) [Work Files](#) [Saved Searches](#) [My Account](#) | [Products](#)

Search: Quick/Number Boolean Advanced

The Delphion Integrated View

Get Now: PDF | [More choices...](#)

Tools: Add to Work File: [Create new Work File](#)

View: [INPADOC](#) | Jump to: [Top](#)

[Email](#)

>Title: **JP2001064194A2: THERAPEUTIC AGENT OF HYPERLIPEMIA AND OF HYPERLIPEMIA**

Country: JP Japan

Kind: A2 Document Laid open to Public inspection!

Inventor: WATANABE YASUO;
EGUCHI FUMIHARU;
KUMAZAKI TAKEHIRO;



Assignee: WATANABE YASUO
EGUCHI FUMIHARU
SHINATSUPUSU:KK
[News, Profiles, Stocks and More about this company](#)

Published / Filed: 2001-03-13 / 1999-08-24

Application Number: **JP1999000237307**

IPC Code: **A61K 35/84; A61P 3/06;**

Priority Number: 1999-08-24 **JP1999000237307**

Abstract:


PROBLEM TO BE SOLVED: To provide a therapeutic agent of hyperlipemia, without a fear of side effect caused by chronic use for a long term, and having high safety.

SOLUTION: This therapeutic agent of hyperlipemia contains an extract of Pleurotus eryngii or a dried powder of the fruit body of the Pleurotus eryngii as an essential component. The Pleurotus eryngii belongs to Basidiomycetes. The fruit body (a mushroom) is commercially sold as eryngii, eryngii mushroom or the like in Japan, and supplied for food.

COPYRIGHT: (C)2001,JPO

Family: None

Other Abstract Info: DERABS C2001-294839 DERABS C2001-294839



[this for the Gallery...](#)

Nominate